title: Cancer Tissue Engineering: A Novel 3D Polystyrene Scaffold for In Vitro Isolation and Amplification of Lymphoma Cancer Cells from Heterogeneous Cell Mixtures.
abstract: Isolation and amplification of primary lymphoma cells in vitro setting is technically and biologically challenging task. To optimize culture environment and mimic in vivo conditions, lymphoma cell lines were used as a test case and were grown in 3-dimension (3D) using a novel 3D tissue culture polystyrene scaffold with neonatal stromal cells to represent a lymphoma microenvironment. In this model, the cell proliferation was enhanced more than 200-fold or 20,000% neoplastic surplus in 7 days when less than 1% lymphoma cells were cocultured with 100-fold excess of neonatal stroma cells, representing 3.2-fold higher proliferative rate than 2D coculture model. The lymphoma cells grew and aggregated to form clusters during 3D coculture and did not maintained the parental phenotype to grow in single-cell suspension. The cluster size was over 5-fold bigger in the 3D coculture by day 4 than 2D coculture system and contained less than 0.00001% of neonatal fibroblast trace. This preliminary data indicate that novel 3D scaffold geometry and coculturing environment can be customized to amplify primary cancer cells from blood or tissues related to hematological cancer and subsequently used for personalized drug screening procedures.
authors.affiliation: 3D Biotek LLC, 675 US Highway 1, North Brunswick, NJ 08902, USA.
authors.forename: Carlos E
authors.initials: CE
authors.lastname: Caicedo-Carvajal
authors.forename: Qing
authors.initials: Q
authors.lastname: Liu
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Remache
authors.forename: Andre
authors.initials: A
authors.lastname: Goy
authors.forename: K Stephen
authors.initials: KS
authors.lastname: Suh
references.citation: Int Rev Cytol. 2003;227:65-130
references.pmid: 14518550
references.citation: Leuk Res. 2006 Apr;30(4):449-57
references.pmid: 16183118
references.citation: Leuk Res. 1986;10(8):1007-13
references.pmid: 3528680
references.citation: Int J Biochem Cell Biol. 2007;39(11):1987-94
references.pmid: 17719831
references.citation: Tissue Eng Part B Rev. 2010 Jun;16(3):351-9
references.pmid: 20092396
references.citation: Sci Transl Med. 2011 Jan 19;3(66):66ra5
references.pmid: 21248315
references.citation: Cell Prolif. 2006 Jun;39(3):217-29
references.pmid: 16671999
references.citation: Stem Cells. 2005 Jun-Jul;23(6):727-37
references.pmid: 15917469
references.citation: Clin Lymphoma Myeloma. 2007 Aug;7 Suppl 5:S184-91
references.pmid: 17877843
references.citation: BMC Cancer. 2010 Jun 07;10:263
references.pmid: 20529269
references.citation: Curr Cancer Drug Targets. 2011 Jun;11(5):613-23
references.pmid: 21486215
references.citation: Future Oncol. 2008 Apr;4(2):149-68
references.pmid: 18407730
references.citation: Biomaterials. 2009 Oct;30(30):6076-85
references.pmid: 19695694
references.citation: Leukemia. 2008 Jan;22(1):49-58
references.pmid: 17914412
references.citation: J Mammary Gland Biol Neoplasia. 2010 Sep;15(3):291-9
references.pmid: 20824492
references.citation: Tissue Eng Part A. 2010 Jul;16(7):2147-52
references.pmid: 20214471
references.citation: Leukemia. 2000 Aug;14(8):1483-9
references.pmid: 10942246
references.citation: Methods Mol Med. 2005;117:83-98
references.pmid: 16118447
references.citation: Mol Pharm. 2008 Sep-Oct;5(5):849-62
references.pmid: 18680382
references.citation: Macromol Biosci. 2009 May 13;9(5):437-43
references.pmid: 19165822
references.citation: Science. 2002 May 10;296(5570):1046-9
references.pmid: 12004111
references.citation: J Urol. 2001 Dec;166(6):2472-83
references.pmid: 11696814
references.citation: Biomaterials. 2011 Jan;32(2):321-9
references.pmid: 20952054
references.citation: J Cell Sci. 2010 Mar 15;123(Pt 6):853-60
references.pmid: 20159965
references.citation: Nat Med. 2007 Aug;13(8):944-51
references.pmid: 17632527
references.citation: Blood. 2009 May 7;113(19):4604-13
references.pmid: 19228923
references.citation: Nat Methods. 2007 Oct;4(10):855-60
references.pmid: 17767164
references.citation: MAbs. 2009 Jan-Feb;1(1):31-40
references.pmid: 20046572
references.citation: Proteomics. 2005 Mar;5(4):978-89
references.pmid: 15712233
references.citation: Pharm Res. 2010 Sep;27(9):1939-48
references.pmid: 20585843
references.citation: Biomaterials. 2005 Mar;26(9):979-86
references.pmid: 15369686
references.citation: Trends Immunol. 2011 Jan;32(1):12-8
references.pmid: 21147035
references.citation: Leukemia. 2007 Jul;21(7):1521-31
references.pmid: 17476277
references.citation: Biol Cell. 2003 Jul;95(5):257-64
references.pmid: 12941523
references.citation: Leuk Res. 2001 Oct;25(10):901-7
references.pmid: 11532524
references.citation: J Clin Oncol. 2009 Feb 1;27(4):481-3
references.pmid: 19075257
references.citation: Immunol Invest. 2006;35(3-4):297-325
references.pmid: 16916756
references.citation: Curr Opin Oncol. 2010 Sep;22(5):424-30
references.pmid: 20679770
references.citation: Eur J Haematol. 2010 Nov;85(5):371-86
references.pmid: 20727006
references.citation: Haematologica. 2009 Nov;94(11):1488-92
references.pmid: 19880776
references.citation: Exp Cell Res. 2010 Oct 15;316(17):2713-22
references.pmid: 20451516
references.citation: Blood. 2000 Sep 15;96(6):2219-25
references.pmid: 10979969
references.citation: Int J Cancer. 2011 Apr 15;128(8):1751-7
references.pmid: 21344372
references.citation: Int J Cancer. 2008 Dec 15;123(12):2759-66
references.pmid: 18798273
references.citation: Exp Hematol. 2005 Jul;33(7):828-35
references.pmid: 15963859
references.citation: BMC Cancer. 2010 Aug 19;10:444
references.pmid: 20723242
references.citation: J Cell Commun Signal. 2011 Aug;5(3):239-48
references.pmid: 21499821